Özet:

Purpose: It is to explore the relationship between alexity and pain, depression, anxiety and central sensitivity scores in temporomandibular joint dysfunction (TMED) patients. Method of treatment: 78 patients diagnosed with TMED with a duration of more than 6 months were evaluated. Visual analog scale (VAS) to assess the intensity of pain; Central Sensitization Scale (SSO) to assess the presence of central sensitivity; Depression and Anxiety Detection Hospital Anxiety Depression Scale (HADS); Toronto Alchemist Scale (TAS) was used to assess the presence of alexity. The study was completed with 62 patients (48 women, 14 men; an average age of 33.7 ± 7.2 years). According to HADS values, 30.6 percent (n=19) of patients were depressed and 21 percent (n=13) were anxiety. According to the SSO, 53.2 percent (n=33) of patients observed central sensitivity. According to the TAS score, 32.3 percent (n=20) of patients had alexity. A significant difference was observed in VAS, HADS and TAS scores compared to patients with and without central sensitivity (p<0,001). In comparison with patients with alchymitis and non-TMED, significant differences were observed in VAS, HADS and SSÖ scores (p<0,01). In 19 (95%) of TMED patients with 20 alexity, central sensitivity was observed according to the SSO scale. The multiple regression analysis found that there was a meaningful relationship between the TAS score and the SSÖ score (p<0,001). The result is that there is a relationship between alchymitis and central sensitivity, and as the severity of central sensitivity increases, the alchymitis scores increase. If you have alexity in TMED patients, central sensitivity can be accompanied by 95%.

Anahtar Kelimeler: